Marina N. Sharifi, MD, University of Wisconsin Carbone Cancer Center, Madison, WI, highlights the exciting advancements in circulating tumor DNA (ctDNA) research presented at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Particularly, she emphasizes the progress made in utilizing ctDNA for minimal residual disease detection in early-stage breast cancer. However, she acknowledges there are still open questions regarding the interpretation of ctDNA tests in this context and how to address positive results. Despite these challenges, the increasing data available is contributing to a better understanding of how to effectively incorporate ctDNA into clinical practice, marking a significant step forward in breast cancer research. This interview was conducted at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
